KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Revenue (2017 - 2025)

Sarepta Therapeutics has reported Revenue over the past 12 years, most recently at $442.9 million for Q4 2025.

  • Quarterly results put Revenue at $442.9 million for Q4 2025, down 32.73% from a year ago — trailing twelve months through Dec 2025 was $2.2 billion (up 15.58% YoY), and the annual figure for FY2025 was $2.2 billion, up 15.58%.
  • Revenue for Q4 2025 was $442.9 million at Sarepta Therapeutics, up from $399.4 million in the prior quarter.
  • Over the last five years, Revenue for SRPT hit a ceiling of $1.1 billion in Q4 2023 and a floor of $22.0 million in Q1 2023.
  • Median Revenue over the past 5 years was $336.1 million (2023), compared with a mean of $363.3 million.
  • Biggest five-year swings in Revenue: plummeted 89.56% in 2023 and later skyrocketed 1778.95% in 2024.
  • Sarepta Therapeutics' Revenue stood at $201.5 million in 2021, then skyrocketed by 285.69% to $777.0 million in 2022, then skyrocketed by 38.75% to $1.1 billion in 2023, then crashed by 38.93% to $658.4 million in 2024, then crashed by 32.73% to $442.9 million in 2025.
  • The last three reported values for Revenue were $442.9 million (Q4 2025), $399.4 million (Q3 2025), and $611.1 million (Q2 2025) per Business Quant data.